Modality
Vaccine
MOA
KRASG12Ci
Target
SHP2
Pathway
Wnt
FabryParkinson's
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
~Apr 2018
→ ~Jul 2019
Phase 3
~Oct 2019
→ ~Jan 2021
NDA/BLA
Apr 2021
→ Jul 2026
NDA/BLACurrent
NCT04306336
532 pts·Fabry
2021-04→2026-07·Not yet recruiting
532 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-073mo awayPh3 Readout· Fabry
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-07-07 · 3mo away
Fabry
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04306336 | NDA/BLA | Fabry | Not yet recr... | 532 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |